Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Assessing the Phase III data in CIC for Plecanatide vs. Linzess and how different CIC vs. IBS-C data is for these drugs

Ticker(s): SGYP, AGN, IRWD

Who's the expert?

Name: Blinded Expert

Bio:

  • Gastroenterologist with over 20 years of experience practicing gastroenterology
  • Trained in all endoscopic procedure and the Orbera intragastric balloon for weight loss
  • Board Certified in Gastroenterology and Internal Medicine

Interview Questions
Q1.

Can you please give some background on your practice and the number of patients you treat with CIC and IBS-C?

Added By: joe_mccann
Q2.

What percent of your CIC patients need medication for treatment rather than diet and other interventions?

Added By: joe_mccann
Q3.

What % of patients have success with OTC laxatives? Are there any patients you see currently in need of medical intervention for CIC, but not on medication?

Added By: joe_mccann
Q4.

Investors are very focused on the Plecanatide diarrhea rate being significantly lower than Linzess' rate. Do you find this to be a problem in the patients you treat with Linzess now?

Added By: joe_mccann
Q5.

How do you currently decide between using Amitiza and Linzess in CIC patients?

Added By: joe_mccann
Q6.

Are CIC patients clearly and consistently different patients than IBS-C patients? IBS-D? - If the patients are not clearly categorized, do you think that Plecanatide will be significantly hindered until approved for both?

Added By: joe_mccann
Q7.

What is the biggest reason constipation sufferers don't currently receive prescription treatment? - Do you see anything in the Plecanatide data that would increase the number of patients seeking treatment?

Added By: joe_mccann
Q8.

Based on the data thus far, do you anticipate success for Plecanatide in IBS-C? - Does an increase in bowel movements typically result in improvements in abdominal pain?

Added By: joe_mccann
Q9.

Can you please discuss some of the key differences between CIC and IBS-C from a therapeutic standpoint? Why do companies need to run 4 trials for seemingly similar illnesses?

Added By: joe_mccann
Q10.

Do you view the data for Plecanatide as markedly clinically superior to Linzess? (Specifically around diarrhea rates)

Added By: joe_mccann
Q11.

How much do you think the addition of a well marketed treatment like Plecanatide will grow the CIC and IBS-C markets?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Related Catalysts Image

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.